
The rapid pace of medical innovation continues to redefine healthcare. In 2024, remarkable breakthroughs—from cancer therapies to treatments for rare diseases—have not only improved lives but also shaped the future of medicine.
Advancements in Cancer Treatment
Enhertu Broadens Scope
Enhertu, an antibody-drug conjugate, now treats breast cancers with lower HER2 levels, combining targeted therapy with chemotherapy for precision care.
Tagrisso’s Early Promise
Tagrisso, already a mainstay for advanced lung cancer, shows potential in preventing recurrence in earlier stages, marking another step forward in cancer prevention.
GLP-1 Medications Beyond Diabetes
GLP-1 drugs, like semaglutide and tirzepatide, have expanded beyond diabetes and weight loss. Semaglutide reduces heart attack and stroke risks, while tirzepatide is the first approved treatment for sleep apnea. Ongoing efforts to develop oral versions promise broader accessibility.
HIV Prevention Breakthrough: Lenacapavir
Gilead’s long-acting injectable, lenacapavir, proved 100% effective in preventing HIV in a large clinical trial. Its twice-yearly dosing offers a major advancement, though global access challenges persist.
Precision Medicine Milestones
- Duvyzat: A nonsteroidal treatment for all genetic types of Duchenne muscular dystrophy.
- Cobenfy: A groundbreaking schizophrenia drug targeting cholinergic receptors.
- Winrevair: The first drug to address pulmonary arterial hypertension at its root cause.
Future Frontiers
From CAR-T therapy for lupus to gene-edited pig organ transplants, 2024 has opened new frontiers. Advances like spinal cord stimulation devices offer renewed hope for mobility.

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE